BMO Capital Maintains Outperform on Eli Lilly and Co, Maintains $1001 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Eli Lilly and Co (NYSE:LLY) with a price target of $1001.
July 03, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman has reiterated an Outperform rating for Eli Lilly and Co (NYSE:LLY) and maintained a price target of $1001.
The reaffirmation of an Outperform rating and a high price target of $1001 by a reputable analyst is likely to boost investor confidence in Eli Lilly and Co, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100